AN2 Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company developing small-molecule therapeutics from a boron chemistry platform. Its disclosures cover common stock registration, operating and financial results, clinical and regulatory updates, risk factors and material events related to its development pipeline.
ANTX filings also include proxy materials for director elections and auditor ratification, 8-K reports on material agreements, equity and warrant financing arrangements, at-the-market sale agreements, equity incentive plan matters, option repricing, officer appointments, governance changes and capital-structure disclosures.
AN2 Therapeutics, Inc. director Gilbert Lynn Marks acquired 2,283 shares of common stock on October 12, 2026, issued in lieu of cash compensation under the issuer's non-employee director compensation policy. The shares vested immediately. His reported direct holdings following the acquisition were 84,156 shares.
AN2 Therapeutics, Inc. director Patricia A. Martin acquired 389 shares of common stock on October 12, 2026, issued in lieu of cash compensation under the issuer's non-employee director compensation policy. The shares vested immediately, and her directly held position afterward was 19,252 shares.
AN2 Therapeutics, Inc. director Aziz Kabeer acquired 2,465 common shares on October 12, 2026, issued in lieu of cash compensation under the issuer’s non-employee director compensation policy; all shares vested immediately. His reported direct holdings after the award were 61,571 shares.
Separate indirect holding entries identify shares held by Adjuvant Global Health Technology Fund, L.P. and Adjuvant Global Health Technology Fund DE, L.P. The footnotes state that Kabeer may be deemed to share voting and dispositive power over those securities, while he and the entities disclaim beneficial ownership except to the extent of their pecuniary interest.
AN2 Therapeutics, Inc. (ANTX) reported that Chief Medical Officer Trenor Cameron C. III received equity awards on September 15, 2026. He was granted 116,667 shares of Common Stock in the form of restricted stock units and a stock option covering 233,333 shares of Common Stock at an exercise price of $5.36 per share, expiring September 14, 2036. The RSUs and option vest over time, subject to his continuous service.
AN2 Therapeutics, Inc. (ANTX) director Robin Shane Readnour reported indirect sales totaling 1,108 shares of common stock on September 9, 2026, at a weighted average price of $6.0243 per share. The sales were made automatically under Rule 10b5-1 trading plans for MGC 2018 LP and MGC 2018 QP. Following these transactions, Readnour continues to hold 9,077 shares of ANTX common stock directly, while disclaiming beneficial ownership of the fund-held shares beyond any pecuniary interest.
AN2 Therapeutics, Inc. (ANTX) director Robin Shane Readnour reported indirect sales of common stock associated with investment funds MGC Venture Partners 2018, LP and MGC Venture Partners QP 2018, LP on September 3 and 8, 2026. The funds sold a total of 16,119 shares at weighted average prices of $6.0183 and $6.0698 per share, for transactions occurring automatically pursuant to Rule 10b5-1 trading plans adopted on April 23, 2026. Readnour has shared voting and dispositive power over these fund-held shares and disclaims beneficial ownership except to the extent of his pecuniary interest; a separate entry shows 9,077 shares of common stock held directly as of September 3, 2026.
AN2 Therapeutics, Inc. (ANTX) reported that Principal Accounting Officer Sarah Joanne Williams sold 272 shares of common stock on September 1, 2026 at $5.53 per share. The sale was made pursuant to the grant terms to satisfy tax withholding obligations arising from RSU vesting on August 28, 2026.
After this transaction, Williams holds 66,311 shares directly, including RSUs that vest through 2029, subject to her continuous service. No Rule 10b5-1 trading plan is reported for this sale.
AN2 Therapeutics, Inc. (ANTX) director Margaret M. FitzPatrick purchased 2,098 shares of ANTX common stock in a direct open-market or private transaction on September 1, 2026 at $5.53 per share. Following this purchase, she directly holds 10,708 shares of ANTX common stock. No Rule 10b5-1 trading plan is reported.
AN2 Therapeutics, Inc. (ANTX) reported that Trenor Cameron C. III, its Chief Medical Officer, filed an initial statement of beneficial ownership on Form 3. The filing lists no reportable transactions or holdings data, serving as the baseline ownership record as this officer becomes a reporting person.
AN2 Therapeutics, Inc. (ANTX) director Robin Shane Readnour reported indirect sales of common stock on August 17, 2026 through investment partnerships MGC Venture Partners 2018, LP and MGC Venture Partners QP 2018, LP under pre-arranged Rule 10b5-1 trading plans. A total of 35,402 shares of ANTX common stock were sold in open-market or private transactions at a weighted average price of $6.0082 per share, with individual trades ranging from $6.00 to $6.07. Readnour is a managing partner of MGC Venture Partners 2018 GP, LLC, which has shared voting and dispositive power over the partnerships’ holdings, and disclaims beneficial ownership of these securities except to the extent of her pecuniary interest. Separately, she reports 9,077 shares of ANTX common stock held directly.